As of 1:22:42 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | -1.95 | -1.85 |
| Low Estimate | 0 | 0 | -1.95 | -1.85 |
| High Estimate | 0 | 0 | -1.95 | -1.85 |
| Year Ago EPS | -- | -- | -- | -1.95 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 2 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.78 | -0.36 | -0.4 | -0.42 |
| EPS Actual | -0.94 | -0.38 | -0.43 | -0.42 |
| Difference | -0.16 | -0.02 | -0.03 | 0 |
| Surprise % | -20.51% | -4.40% | -8.18% | 0.47% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -1.95 | -1.85 |
| 7 Days Ago | 0 | 0 | 0 | -1.85 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | 1 | 1 |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ATXS | -- | -- | -- | 5.13% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/27/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 8/13/2024 |
Related Tickers
SYRE Spyre Therapeutics, Inc.
24.85
+3.03%
PHVS Pharvaris N.V.
18.35
-0.27%
SLRN Acelyrin, Inc.
3.4100
+5.57%
LXEO Lexeo Therapeutics, Inc.
7.00
+1.67%
COGT Cogent Biosciences, Inc.
8.48
+3.99%
ANAB AnaptysBio, Inc.
16.91
+8.47%
OKUR OnKure Therapeutics, Inc.
9.49
-3.75%
VRDN Viridian Therapeutics, Inc.
22.86
+28.05%
NRIX Nurix Therapeutics, Inc.
21.15
+4.34%
OLMA Olema Pharmaceuticals, Inc.
6.48
-4.07%